Advancedadvt Limited Completion of Disposal of Synaptic Software

RNS Number : 1332B

Advancedadvt Limited

29 January 2024

 

29 January 2024

 

AdvancedAdvT Limited

 

Completion of Disposal of Synaptic Software Limited

 

AdvancedAdvT Limited (AIM: ADVT, "AdvT", the "Company"), the international software solutions provider for the business solutions, healthcare compliance, and human capital management sectors, announces that it has completed the disposal of Synaptic Software Limited following FCA approval. Full details of the disposal were set out in the Company's AIM admission document published on 8 January 2024, which is available on its website at www.advancedadvt.com.

 

Enquiries:

 

AdvancedAdvT Limited
Vin Murria, Chairperson Gavin Hugill, Chief Financial Officer	c/o Meare Consulting
Singer Capital Markets (Nominated Adviser and Broker)	Tel: [phone]
Philip Davies / Asha Chotai / Sam Butcher
KK Advisory (Investor Relations)	Tel: [phone]
Kam Bansil

 

Meare Consulting
Adrian Duffield	Tel: [phone]

 

Note to Editors

 

AdvancedAdvT Limited (AdvT) provides software solutions and platforms across two business transformational areas: business solutions & healthcare compliance, and human capital management.

 

The Group's operations are IBSS (financial management software), CHKS (AI based healthcare intelligence compliance and accreditation software), Retain (global resource planning and talent management software) and WFM (workforce management software provider).

 

AdvT is an agent for change. The Group enables the delivery of Artificial Intelligence ("AI"), data analytics and business intelligence, all of which are key future drivers for growth in these sectors where long term digitisation trends are set to transform the workplace for professionals. 

 

AdvT is developing both organically and through acquisitions, by expanding its presence across adjacent markets, geographical boundaries and digital sectors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

DISSEDFUAELSEEF